Key statistics
As of last trade Lineage Cell Therapeutics Inc (LCTX:TLV) traded at 192.50, 3.05% above its 52-week low of 186.80, set on Nov 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 188.00 |
---|---|
High | 196.90 |
Low | 188.00 |
Bid | 188.90 |
Offer | 192.50 |
Previous close | 189.50 |
Average volume | 83.30k |
---|---|
Shares outstanding | 188.84m |
Free float | 188.00m |
P/E (TTM) | -- |
Market cap | 95.16m USD |
EPS (TTM) | -0.1096 USD |
Data delayed at least 20 minutes, as of Nov 25 2024 09:44 GMT.
More ▼
Press releases
- Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
- Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
- Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
- Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
- OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
- Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
More ▼